The DOI matches its Crossref record, with a small difference in title or year; 44 of the 44 references it cites were found in a registry or an index.
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial
Open accessAbstract
Background and objectives: Diabetic kidney disease is an important complication of type 2 diabetes. In a phase 2b study, adding esaxerenone to renin-angiotensin system inhibitors dose dependently reduced the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and microalbuminuria. This 52-week phase 3 study further investigated the effects of esaxerenone on the urinary albumin-to-creatinine ratio in this patient group. Design, setting, participants, & measurements: In this multicenter, randomized, double-blind study, patients with type 2 diabetes and a urinary albumin-to-creatinine ratio of 45 to <300 mg/g creatinine treated with renin-angiotensin system inhibitors were randomized to esaxerenone or placebo for 52 weeks ( n =455). Esaxerenone was initiated at 1.25 mg/d and titrated to 2.5 mg/d on the basis of serum potassium monitoring. The primary endpoint was the proportion of patients achieving urinary albumin-to-creatinine ratio remission (<30 mg/g creatinine and ≥30% reduction from baseline on two consecutive occasions). Results: Overall, 49 (22%) and nine (4%) patients in the esaxerenone and placebo groups, respectively, achieved urinary albumin-to-creatinine ratio remission (absolute difference 18%; 95% confidence interval, 12% to 25%; P< 0.001). The percent change in urinary albumin-to-creatinine ratio from baseline to end of treatment was significantly higher with esaxerenone versus placebo (−58% versus 8%; geometric least-squares mean ratio to placebo 0.38, 95% confidence interval, 0.33 to 0.44). There was a significant improvement with esaxerenone versus placebo in time to first remission (hazard ratio, 5.13; 95% confidence interval, 3.27 to 8.04) and time to first transition to urinary albumin-to-creatinine ratio ≥300 mg/g creatinine (hazard ratio, 0.23; 95% confidence interval, 0.11 to 0.48). More patients had a serum potassium level ≥6.0 or ≥5.5 mEq/L on two consecutive measurements in the esaxerenone group (20 [9%]) versus placebo (5 [2%]); these events were asymptomatic and resolved after dosage reduction or treatment discontinuation. Conclusions: Adding esaxerenone to existing renin-angiotensin system inhibitor therapy in patients with type 2 diabetes and microalbuminuria increased the likelihood of albuminuria returning to normal levels, and reduced progression of albuminuria to higher levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Novel nonsteroidal MRA, such as fi nerenone and esaxerenone, are more selective for mineralocorticoid receptors and have been noted to offer similar reductions in albuminuria but with a lower risk of hyperkalemia.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esaxerenone lowered BP and albuminuria with limited changes in potassium, but long-term studies with clinical end points are lacking (85).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Esaxerenone, another ns-MRA, has also been shown to lower urinary albumin excretion.”
The cited source says what the claim attributes to it.
In the citing paper
“However, the long-term kidney and cardiovascular bene fi ts of esaxerenone have not been established, and regulatory approval for esaxerenone is not widespread.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to fi nerenone, another nonsteroidal MRA, esaxerenone, has also been shown to lower albumin excretion.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., & Hishida, A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.034 · Cited by 6,422
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Self-citation
Cited by
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Diabetes Care · doi:10.2337/dci22-0027 · Cited by 919
“Esaxerenone lowered BP and albuminuria with limited changes in potassium, but long-term studies with clinical end points are lacking (85).”
BackgroundMolecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.012 · Cited by 353
“Esaxerenone lowered BP and albuminuria with limited changes in potassium, but long-term studies with clinical end points are lacking (85).”
BackgroundRossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
“However, the long-term 994 kidney and cardiovascular benefits of esaxerenone have not been established, and regulatory approval for esaxerenone is, so far, limited to treatment of hypertension in Japan.28,29 The Work Group judged that the majority of wellinformed patients with T2D who had persistent albuminuria (ACR >…”
BackgroundHyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial
Agarwal, R., Joseph, A., Anker, S. D., Filippatos, G., Rossing, P., Ruilope, L. M., Pitt, B., Kolkhof, P., Scott, C., Lawatscheck, R., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070942 · Cited by 262
“4% of patients receiving placebo.(23,24) Another steroidal MRA, eplerenone, which is more selective than spironolactone, approximately doubles the risk of hyperkalemia in patients with heart failure,(25,26) and is contraindicated in patients with T2D and moderately elevated albuminuria without heart failure (in the US…”
BackgroundBarrera-Chimal, J., Lima-Posada, I., Bakris, G. L., & Jaisser, F. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00490-8 · Cited by 252
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Kintscher, U., Bakris, G. L., & Kolkhof, P. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15747 · Cited by 173
Chronic Kidney Disease: Strategies to Retard Progression
Yan, M.-T., Chao, C., & Lin, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810084 · Cited by 187
Novel Insights into Diabetic Kidney Disease
Młynarska, E., Buławska, D., Czarnik, W., Hajdys, J., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810222 · Cited by 166
“While esaxerenone has been shown to reduce blood pressure and albuminuria, long-term studies evaluating its effect in patients with DKD are still lacking [106].”
BackgroundStanciu, S. M., Rusu, E., Miricescu, D., Radu, A. C., Axinia, B., Vrabie, A.-M., Ionescu, R. F., Jinga, M., & Sîrbu, C. A. (2023) · Metabolites · doi:10.3390/metabo13010087 · Cited by 144
Combination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
“In the ESAX-DN study, which included 455 patients with T2DM and UACR 45 to 300 mg/g who were treated with RAS inhibitors, esaxerenone markedly reduced microalbuminuria compared with placebo 56 .”
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Wang, N., & Zhang, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063086 · Cited by 139
“…clinical trial of Esaxerenone with Placebo in Japanese Type 2 Diabetic Patients with Microalbuminuria (ESAX-DN) failed to show a protective effect for the progression of DKD due to a short study duration with participants in early DKD or other unique characteristics of a single-country study [154].”
BackgroundOhya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 106
Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities
Przezak, A., Bielka, W., & Pawlik, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126500 · Cited by 116
“Moreover, a phase III clinical trial Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN) demonstrated that, in patients with T2D and microalbuminuria, an addition of esaxerenone to hypertension therapy resulted in a reduced progression of albuminuria [102].”
BackgroundKolkhof, P., Joseph, A., & Kintscher, U. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105859 · Cited by 94
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Morales, J., & Handelsman, Y. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.052 · Cited by 93
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Pandey, A. K., Bhatt, D. L., Cosentino, F., Marx, N., Rotstein, O. D., Pitt, B., Pandey, A., Butler, J., & Verma, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac299 · Cited by 95
Lv, R., Xu, L., Che, L., Liu, S., Wang, Y., & Dong, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1125693 · Cited by 80
Aldosterone and cardiovascular diseases
Parksook, W. W., & Williams, G. H. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac027 · Cited by 72
Diagnosis and management of resistant hypertension
Schiffrin, E. L., & Fisher, N. D. L. (2024) · BMJ · doi:10.1136/bmj-2023-079108 · Cited by 81
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Verma, S., Pandey, A., Pandey, A. K., Butler, J., Lee, J. S., Teoh, H., Mazer, C. D., Kosiborod, M., Cosentino, F., Anker, S. D., et al. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00419.2023 · Cited by 76
Ortíz, A., Ferro, C. J., Balafa, O. C., Burnier, M., Ekart, R., Halimi, J., Kreutz, R. H., Mark, P. B., Persu, A., Rossignol, P., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab167 · Cited by 69
Georgianos, P. I., & Agarwal, R. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac124 · Cited by 69
Savarese, G., Lindberg, F., Filippatos, G. S., Butler, J., & Anker, S. D. (2023) · Diabetologia · doi:10.1007/s00125-023-06031-1 · Cited by 68
“In ESAX-DN, a 52 week double-blind Phase III RCT enrolling 455 patients with DKD on RAS inhibitor therapy, esaxerenone improved albuminuria vs placebo (HR for time to first remission of albuminuria: 5.13; 95% CI 3.27, 8.04) [136].”
BackgroundInfluentialAdverse Effects of Aldosterone: Beyond Blood Pressure
Brown, J. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030142 · Cited by 65
“…trial of patients with hypertension and diabetes with microalbuminuria, esaxerenone treatment resulted in a greater reduction in albuminuria, 95 and in an open-label study in patients with primary aldosteronism, esaxerenone has been demonstrated to have significant efficacy for BP lowering,…”
BackgroundKintscher, U., & Edelmann, F. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01899-0 · Cited by 62
“Significant renoprotective actions have been described for esaxerenone and finerenone [6, 7, 39].”
BackgroundMineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials
Oraii, A., Healey, J. S., Kowalik, K., Pandey, A. K., Benz, A. P., Wong, J. A., Conen, D., & McIntyre, W. F. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad811 · Cited by 58
Renin–Angiotensin–Aldosterone System: From History to Practice of a Secular Topic
Ksiazek, S. H., Hu, L., Andò, S., Pirklbauer, M., Säemann, M. D., Ruotolo, C., Zaza, G., Manna, G. L., Nicola, L. D., Mayer, G. J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074035 · Cited by 57
“Hyperkalemia ≥ 5.5 mmol/L was present in 9% and 5.4% of patients and was generally increased within the first two weeks of treatment and more likely occurred in patients with an eGFR 60 mL/min/1.73 m 2 [42,49,55].”
BackgroundInfluentialTreating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
Mullen, N., Curneen, J. M. G., Donlon, P. T., Prakash, P., Bancos, I., Gurnell, M., & Dennedy, M. C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad026 · Cited by 56
Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
Fioretti, F., Testani, J. M., Tio, M. C., Pitt, B., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.012 · Cited by 56
Barrera‐Chimal, J., Kolkhof, P., Lima‐Posada, I., Alexandre, J., Rossignol, P., & Jaisser, F. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2002844 · Cited by 54
McGill, J. B., Haller, H. G., Roy‐Chaudhury, P., Cherrington, A., Wada, T., Wanner, C., Ji, L., & Rossing, P. R. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002806 · Cited by 57
Self-citationKobayashi, M., Pitt, B., Ferreira, J. P., Rossignol, P., Girerd, N., & Zannad, F. M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf225 · Cited by 53
Whitlock, R. H., Leon, S. J., Manacsa, H., Askin, N., Rigatto, C., Fatoba, S., Farag, Y. M. K., & Tangri, N. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad101 · Cited by 49
Sarafidis, P. A., Iatridi, F., Ferro, C. J., Alexandrou, M. E., Fernández‐Fernández, B., Kanbay, M., Mallamaci, F., Nistor, I., Rossignol, P., Wanner, C., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad139 · Cited by 48
“…in Patients with Type 2 Diabetes and Microalbuminuria ( ESAX-DN ) study, 455 patients with T2D and UACR ≥ 45– 300 mg/g were randomized to receive esaxerenone 1.25 mg/day, up-titrated to 2.5 mg/day based on serum potassium levels, or placebo on top of a RAS blocker for 52 weeks [ 100 ].”
MethodInfluentialMineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Kawanami, D., Takashi, Y., Muta, Y., Oda, N., Nagata, D., Takahashi, H., & Tanabe, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.754239 · Cited by 45
Mineralocorticoid Antagonism in Heart Failure
Chang, J., Ambrosy, A. P., Vardeny, O., Spall, H. G. C. V., Mentz, R. J., & Sauer, A. J. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.007 · Cited by 46
Gaddy, A. R., Elrggal, M. E., Madariaga, H. M., Kelly, A., Lerma, E. V., & Colbert, G. B. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101848 · Cited by 44
Chronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 42
“Phase 2 clinical trials with esaxerenone [131] and apararenone [132] in DKD show that these agents may reduce proteinuria by 40–60% when added on RASi.”
BackgroundIto, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02075-y · Cited by 41
“In addition, a 52-week phase III study demonstrated that the percent change in UACR from baseline to the end of treatment was significantly higher with esaxerenone versus placebo in patients with type 2 diabetes and microalbuminuria treated with RAS inhibitors [23].”
BackgroundMethodSelf-citationLerma, E., White, W. B., & Bakris, G. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2022.2060598 · Cited by 39
“erenone was effective in lowering BP in patients with essential hypertension [45], and was associated with a higher incidence of urinary albumin remission in patients with T2D and high levels of albuminuria who were receiving a RAS inhibitor [46].”
BackgroundKario, K., Ohbayashi, H., Hashimoto, M., Itabashi, N., Kato, M., Uchiyama, K., Hirano, K., Nakamura, N., Miyamoto, T., Nagashima, H., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01762-z · Cited by 39
“In addition to its potent antihypertensive effect, esaxer-enone has been shown to exert UACR-lowering effects in hypertensive patients with diabetic kidney disease, similar to fi nerenone [19, 29 – 31].”
BackgroundUchida, H. A., Nakajima, H., Hashimoto, M., Nakamura, A., Nunoue, T., Murakami, K., Hosoya, T., Komoto, K., Taguchi, T., Akasaka, T., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02294-z · Cited by 40
“However, a previous placebocontrolled esaxerenone clinical trial has confirmed the significant antihypertensive and UACR-lowering actions of the drug [27, 43].”
InfluentialTsukamoto, S., Morita, R., Yamada, T., Urate, S., Azushima, K., Uneda, K., Kobayashi, R., Kanaoka, T., Wakui, H., & Tamura, K. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110161 · Cited by 41
Mende, C. W., Samarakoon, R., & Higgins, P. J. (2023) · American Journal of Nephrology · doi:10.1159/000528783 · Cited by 39
Nuclear receptors in renal health and disease
Luan, Z., Zhang, C., Ming, W., Huang, Y., Guan, Y., & Zhang, X. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103855 · Cited by 39
Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
Baran, W., Krzemińska, J., Szlagor, M., Wronka, M., Młynarska, E., Franczyk, B., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189995 · Cited by 35
“The present study demonstrated that the combined therapy led to an increased percentage of patients with a 30% reduction in UACR (69%) [24].”
BackgroundMethodResultInfluentialNonsteroidal and Steroidal Mineralocorticoid Antagonists
Harrington, J., Canonico, M. E., Rafei, A. E., Solomon, S. D., Teerlink, J. R., Vaduganathan, M., Zieroth, S. R., Bonaca, M. P., & Sauer, A. J. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102637 · Cited by 33
Maresin 1 Alleviates Diabetic Kidney Disease via LGR6‐Mediated cAMP‐SOD2‐ROS Pathway
Li, X., Xu, B.-T., Wu, J. T., Pu, Y., Wan, S., Zeng, Y., Wang, M., Luo, L., Zhang, F., Jiang, Z., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7177889 · Cited by 36
“In addition, study shows adding mineralocorticoid antagonist to existing RAS inhibitor therapy in patients with type 2 diabetes (T2DM) and microalbuminuria reduce progression of albuminuria to higher levels [24, 25].”
BackgroundMineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Hojs, N. V., Bevc, S., Ekart, R., Piko, N., Petreski, T., & Hojs, R. (2021) · Pharmaceuticals · doi:10.3390/ph14060561 · Cited by 30
Palmer, B. F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15030 · Cited by 30
Kario, K., Nishizawa, M., Kato, M., Ishii, H., Uchiyama, K., Nagai, M., Takahashi, N., Asakura, T., Shiraiwa, T., Yoshida, T., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01292-0 · Cited by 30
“Because esaxerenone continuously reduces UACR up to 6 months after administration, followed by a steady state [17], further UACR reduction can be expected with long-term administration.”
BackgroundMineralocorticoid receptor signalling in primary aldosteronism
Yang, J., Young, M. J., Cole, T. J., & Fuller, P. J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0249 · Cited by 29
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
Shah, M., Awad, A. S., & Abdel‐Rahman, E. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196285 · Cited by 30
“Other nonsteroidal MRAs like esaxerenone (CS-3150) have been shown to reduce albuminuria to normal levels if added to the regimen in patients already receiving therapy with RAAS inhibition drugs [49].”
Fernando, K., Connolly, D. L., Darcy, E., Evans, M., Hinchliffe, W., Holmes, P., & Strain, W. D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01738-3 · Cited by 31
A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease
Liu, C., Yang, M., Li, L., Luo, S., Yang, J., Li, C., Liu, J., & Sun, L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.909569 · Cited by 34
Jo, R., Shibata, H., Kurihara, I., Yokota, K., Kobayashi, S., Murai‐Takeda, A., Mitsuishi, Y., Hayashi, T., Nakamura, T., & Itoh, H. (2022) · Hypertension Research · doi:10.1038/s41440-022-01036-6 · Cited by 29
Oda, Y., Nishi, H., & Nangaku, M. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151431 · Cited by 30
Self-citationAldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
Mazzieri, A., Timio, F., Patera, F., Trepiccione, F., Bonomini, M., & Reboldi, G. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000542621 · Cited by 27
“In ESAX-DN [65], 455 patients with type 2 diabetes and microalbuminuria were randomized to esaxerenone or placebo.”
Fujii, W., & Shibata, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097719 · Cited by 31
The renin-angiotensin-aldosterone system: An old tree sprouts new shoots
Ruan, Y., Yu, Y., Wu, M., Jiang, Y., Qiu, Y., & Ruan, S. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111426 · Cited by 28
Clinical implications of mineralocorticoid receptor overactivation
Mouhayyar, C. E., Chhikara, M., Tang, M., & Nigwekar, S. U. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae346 · Cited by 26
“Additionally, the ESAX-DN trial explored esaxerenone’s efficacy and safety in type 2 diabetes ( T2D) patients with microalbuminuria, showing positive outcomes but with a higher incidence of hyperkalemia compared to the placebo ( 4% vs 0.4% of patients, respectively) [71 ].”
InfluentialNovel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease—From Bench to Bedside
Nicholas, S. B. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.010 · Cited by 27
Clinical implications and guidelines for CKD in type 2 diabetes
Zhang, R. M., Persson, F., McGill, J. B., & Rossing, P. R. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac285 · Cited by 27
Rossing, P. R. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.005 · Cited by 25
“The study demonstrated that esaxerenone induced significant remission of moderately increased albuminuria in T2D (n 1⁄4 455) when added to RAS inhibition for 52 weeks, compared with RAS inhibitors alone.(56) Overall, 49 patients (22%) and 9 patients (4%) in the esaxerenone and placebo groups, respectively, achieved UA…”
MethodYamamoto, E., Usuku, H., Sueta, D., Suzuki, S., Nakamura, T., Matsui, K., Matsushita, K., Iwasaki, T., Sakaino, N., Sakanashi, T., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02780-6 · Cited by 25
“…were 35.0% and 3.3%, respectively, and were similar to those reported in a series of Phase 3 studies of esaxerenone including hypertensive patients with essential hypertension [22, 23], moderate renal impairment [25], type 2 diabetes with albuminuria [26, 28, 29], and primary aldosteronism [27].”
BackgroundResultInfluentialEfficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
Oiwa, A., Hiwatashi, D., Takeda, T., Miyamoto, T., Kawata, I., Koinuma, M., Yamazaki, M., & Komatsu, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad144 · Cited by 25
Tezuka, Y., & Ito, S. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01177-6 · Cited by 24
Self-citationExploring molecular targets in diabetic kidney disease
Maruno, S., Tanaka, T., & Nangaku, M. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.251 · Cited by 24
Self-citationGhose, S., Satariano, M., Korada, S., Cahill, T., Shah, R., & Raina, R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00026.2024 · Cited by 23
Jiang, X., Zhang, Z., Li, C., Zhang, S., Su, Q., Yang, S., Liu, X., Hu, Y., & Pu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.896947 · Cited by 22
“Five RCTs (Bakris et al., 2015; Ito et al., 2019; Bakris et al., 2020; Ito et al., 2020; Pitt et al., 2021) reported the incidence of hyperkalemia involving finerenone and esaxerenone, as shown in Figure 6.”
BackgroundMethodInfluentialKatsuya, T., Inobe, Y., Uchiyama, K., Nishikawa, T., Hirano, K., Kato, M., Fukui, T., Hatta, T., Iwasaki, A., Ishii, H., et al. (2024) · Hypertension Research · doi:10.1038/s41440-023-01519-0 · Cited by 22
“This organ-protective effect of esaxerenone in lowering UACR and NT-proBNP has been con fi rmed in phase 3 studies [26, 29, 31, 32] and a post-marketing clinical study, EX-DKD [36].”
BackgroundNovel Therapies for Kidney Disease in People With Diabetes
Khurana, N., James, S., Coughlan, M. T., MacIsaac, R. J., & Ekinci, E. I. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab639 · Cited by 23
Update on Hypertension Research in 2021
Mogi, M., Maruhashi, T., Higashi, Y., Masuda, T., Nagata, D., Nagai, M., Bokuda, K., Ichihara, A., Nozato, Y., Toba, A., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-00967-4 · Cited by 24
“[140] reported that add-on treatment using esaxerenone with maximal tolerable doses of a reninangiotensin system (RAS) inhibitor reduced the urinary 1286 M.”
BackgroundChen, Q., Liang, Y., Yan, J., Du, Y., Li, M., Chen, Z., & Zhou, J. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110210 · Cited by 21
Yoshida, Y., Fujiwara, M., Kinoshita, M., Sada, K., Miyamoto, S., Ozeki, Y., Iwamoto, M., Mori, Y., Nagai, S., Matsuda, N., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01412-w · Cited by 20
Patel, S. K., Teoh, H., Saunthar, A., Yau, T. M., & Verma, S. (2025) · Cardiac failure review · doi:10.15420/cfr.2025.09 · Cited by 22
“70 In the Phase III multicentre, randomised, ESAX-HTN study (NCT02890173), 1,001 patients with essential hypertension were enrolled.”
Ravid, J. D., & Laffin, L. J. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01750-0 · Cited by 22
Motoki, H., Inobe, Y., Fukui, T., Iwasaki, A., Hiramitsu, S., Koyama, S., Masuda, I., Sekimura, N., Yamamoto, K., Sato, A., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02633-8 · Cited by 19
“In the phase 3 placebo-controlled trial (ESAX-DN) [28] in hypertensive patients with T2DM associated with microalbuminuria under treatment with RAS inhibitor, the changes in office BP at 12 and 24 weeks were - 8.9/ - 3.7 mmHg and - 13.1/ - 6.0 mmHg, respectively; these results were consistent with…”
BackgroundResultInfluentialNew ways of mitigating aldosterone in cardiorenal disease
Götzinger, F., Kunz, M., Lauder, L., Böhm, M., & Mahfoud, F. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae049 · Cited by 19
Barrera‐Chimal, J., Gerarduzzi, C., Rossignol, P., & Jaisser, F. (2022) · Clinical Science · doi:10.1042/cs20220212 · Cited by 19
“(75-77) A major challenge will be the uptake and implementation of novel therapeutic options into the daily clinical practice in CKD patients.”
BackgroundSolis‐Herrera, C., & Triplitt, C. L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15327 · Cited by 18
“Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker; BID, twice daily; CI, confidence interval; CKD, chronic kidney disease; DBP, diastolic blood pressure; DKD, diabetic kidney disease; DN, diabetic nephropathy; DR, diabetic retinopathy; eGFR, estimated gl…”
BackgroundHelmeczi, W., & Hundemer, G. L. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001067 · Cited by 18
Shikata, K., Ito, S., Kashihara, N., Nangaku, M., Wada, T., Okuda, Y., Sawanobori, T., & Sugimoto, K. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13778 · Cited by 18
“Empagliflozin 13 (6) 0 (0) 13 (23) 11 (5) 0 (0) 11 (22) 1 (2) 0 (0) 1 (9)”
Self-citationOkuda, Y., Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Sawanobori, T., & Taguri, M. (2022) · Hypertension Research · doi:10.1038/s41440-022-01008-w · Cited by 18
“Other details of the study population, such as the inclusion and exclusion criteria, have been previously published [15].”
BackgroundMethodResultSelf-citationSridhar, V. S., Liu, H., & Cherney, D. Z. I. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.02.324 · Cited by 18
Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease
Górriz, J. L., González‐Juanatey, J. R., Fácila, L., Soler, M. J., Valle, A., & Ortíz, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.002 · Cited by 18
Shenoy, S. V., Nagaraju, S. P., Bhojaraja, M. V., Prabhu, R., Rangaswamy, D., & Rao, I. R. (2021) · Nephrology · doi:10.1111/nep.13917 · Cited by 18
“This was a small phase 3 RCT which randomly assigned 449 patients with type 2 DM and UACR 45–300 mg/g to receive esaxarenone or placebo.(73) At the end of 52 weeks, remission of albuminuria was found in 22% of patients on esaxerenone, compared with 4% on placebo with hyperkalemia in only 9% of patients.”
MethodЈаnkovic, S., & Janković, S. V. (2022) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-022-00760-1 · Cited by 17
“A phase 3 study (JapiCTI-173695; ESAX-DN)—a randomized, double-blind, placebo-controlled clinical trial— also evaluated the antialbuminuric effect and safety of esaxerenone added to renin–angiotensin inhibitor therapy in Japanese patients with type 2 diabetes accompanied by microalbuminuria (urinary albumin/creatinine…”
MethodNetwork meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
Wu, Y., Lin, H., Tao, Y., Xu, Y., Chen, J., Jia, Y., & Zheng, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967317 · Cited by 19
Mineralocorticoid receptor antagonists in cardiovascular translational biology
CHILTON, R. J., & Silva‐Cardoso, J. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000289 · Cited by 17
Targeting renal damage: The ACE2/Ang-(1–7)/mas axis in chronic kidney disease
Zheng, J., & Hao, H. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111413 · Cited by 17
Damianaki, A., Polychronopoulou, E., Wuerzner, G., & Burnier, M. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00495-1 · Cited by 20
Young, M. J., Kanki, M., Karthigan, N., & Konstandopoulos, P. (2021) · Endocrinology · doi:10.1210/endocr/bqab105 · Cited by 16
Liu, W., & Yu, S. (2022) · Kidney Diseases · doi:10.1159/000528066 · Cited by 17
Strizzi, C. T., D’Ambrosio, V., Grandaliano, G., & Pesce, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188829 · Cited by 15
“Emerging non-steroidal MRAs, including esaxerenone and apararenone, have shown promise in specific patient populations, reducing albumin-uria particularly within hypertensive and diabetic cohorts, yet require broader validation through global trials [147,148].”
Yoshida, Y., & Shibata, H. (2024) · Hypertension Research · doi:10.1038/s41440-024-01970-7 · Cited by 15
“In the ESAX-DN study [30], esaxerenone reduced urinary albumin excretion and lowered BP in patients with type 2 diabetes mellitus complicated by chronic kidney disease.”
Zachariah, T. P., & Radhakrishnan, J. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000540 · Cited by 13
Miyasako, K., Maeoka, Y., & Masaki, T. (2024) · Biomedicines · doi:10.3390/biomedicines13010053 · Cited by 15
“A robust body of evidence supporting the clinical utility of non-steroidal MRAs has now accumulated, particularly with respect to patients with hypertension [10,11] or chronic kidney disease (CKD) with type 2 diabetes (T2DM) [12–14].”
Influential
Metadata
- Authors
- Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T.
- Affiliations
- Tohoku University (JP)
- Kawasaki Medical School (JP)
- Okayama University Hospital (JP)
- The University of Tokyo (JP)
- Kanazawa University (JP)
- Daiichi-Sankyo (Japan) (JP)
- Corresponding author
- Ito, Sadayoshi
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2020-11-25
- Volume
- 15
- Issue
- 12
- Pages
- 1715-1727
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC7769030
- OpenAlex
- W3107151441
- Cited by
- 234
- References
- 42
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 46 · 2023: 46 · 2022: 46 · 2021: 25 · 2020: 1
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Daiichi Sankyo Co., Ltd
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- One, type 2 diabetes, microalbuminuria, diabetic nephropathy, albumin-creatinine ratio, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists, serum potassium, renal protection, hospitalization
- MeSH terms
- Aged, Albuminuria, Mineralocorticoid Receptor Antagonists, Creatinine, Diabetes Mellitus, Type 2, Female, Humans, Japan, Kidney, Male, Middle Aged, Pyrroles, Remission Induction, Risk Factors, Sulfones, Time Factors, Biomarkers, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.